Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint

Cullinan Therapeutics, Inc.

Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.
Net loss of $47.6M in Q4 2024 (vs $23.8M Q4 2023); FY 2024 net loss $167.4M (vs $153.2M).
R&D expenses $40.5M Q4 2024 (vs $34.8M); G&A $14.6M (vs $10.6M) year-over-year.
Zipalertinib Phase 2b met primary endpoint (ORR); full results mid-2025; NDA submission planned H2 2025.
Initial CLN-978 SLE data expected Q4 2025; CLN-619 endometrial/cervical cancer data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.